Patient Feedback

Business

Beta Bionics Faces FDA Warning Letter, Assures No Impact on Product Pipeline or Financials

The medical device developer Beta Bionics has received a warning letter from the U.S. Food and Drug Administration, a regulatory action stemming from a facility inspection last summer. The company maintains the letter will not disrupt its operations, manufacturing, or the planned launch of its new insulin patch pump.

Feb 2, 2026

Business

Salesforce: A 2025 Stumble Sets Stage for Potential 2026 Rebound

While many AI stocks soared in 2025, Salesforce shares faced significant headwinds. Despite a challenging year, the cloud software giant's robust fundamentals and reasonable valuation suggest it may be poised for a recovery.

Feb 2, 2026

Business

Analysts Trim MiMedx Targets Amid Regulatory Shifts in Wound Care Coverage

Craig-Hallum and Northland Securities have both lowered price targets for MiMedx Group (MDXG), citing near-term uncertainty following new CMS billing guidance for skin substitute products, though both firms maintain positive long-term ratings.

Feb 2, 2026

Business

GrainCorp Shares Show Potential Value Gap: DCF Analysis Points to Undervaluation

A discounted cash flow valuation of GrainCorp Limited suggests its current share price may not fully reflect its future cash generation potential, indicating a possible opportunity for investors.

Feb 2, 2026

Business

iRhythm's Reset: Analysts Recalibrate Price Targets Amid Shifting Market Sentiment

A significant reset in analyst price targets for iRhythm Holdings (IRTC) is prompting investors to reassess the cardiac monitoring firm's risk-reward profile. This shift reflects evolving views on reimbursement headwinds, competitive pressures, and long-term growth catalysts in the digital health sector.

Feb 2, 2026

Business

Novo Nordisk Advances Oral Obesity Pill and Cell Therapy Pipeline Amid Market Reassessment

Novo Nordisk launches its first oral GLP-1 weight-loss drug with strong early demand, reports positive Phase 3 results for CagriSema, and expands a cell therapy partnership for diabetes. These moves come as investors reevaluate the company's long-term growth prospects amid competitive and pricing pressures.

Feb 2, 2026

Business

Cramer Advises Caution on Rubrik: "Wait for the Shakeout"

CNBC's Jim Cramer offered a measured take on data security firm Rubrik (NYSE:RBRK), suggesting investors wait for market volatility to settle before considering a position, while highlighting the crowded nature of the sector.

Feb 2, 2026

Business

Fed Holds Rates Steady Amid Economic Strength, Defying White House Pressure

The Federal Reserve left interest rates unchanged, signaling confidence in a solid economy while inflation remains above target. The decision sets up a continued clash with a President demanding deeper cuts.

Feb 2, 2026

Business

Dropbox Stock Slump Sparks Value Debate: Is DBX a Hidden Gem or a Fading Star?

Dropbox shares have faced significant pressure over the past year, declining roughly 20% and raising questions about its long-term growth trajectory. As the stock trades below key fair value estimates, investors are divided on whether this represents a buying opportunity or reflects deeper challenges in the competitive cloud storage market.

Feb 2, 2026

Business

G Mining Ventures Sees CA$1.3B Market Cap Slide, But Institutional Backers Hold Steady Amid Long-Term Gains

Despite a significant weekly drop in market valuation, G Mining Ventures' substantial institutional ownership and strong yearly returns suggest major investors are focused on the long game, even as recent volatility raises questions.

Feb 2, 2026

Business

Seeking Shelter in Dividends: Three ASX Stocks for a Turbulent February 2026

With interest rate uncertainty and global headwinds buffeting markets, income-focused investors are turning to dividend-paying stocks for potential stability. We examine three ASX-listed companies offering yields above 3%, assessing their resilience in the current climate.

Feb 2, 2026

Business

Insider Confidence: Three ASX Stocks Poised for Strong Earnings Growth Amid Market Uncertainty

As investors navigate a complex economic landscape, companies with significant insider ownership and robust earnings forecasts are drawing attention. We examine three ASX-listed firms where leadership's skin in the game aligns with ambitious growth projections.

Feb 2, 2026

Business

Market Jitters Uncover Hidden Gems: ASX Stocks Like Capricorn Metals Trading at Steep Discounts

Amid a volatile market backdrop, several ASX-listed companies, including gold miner Capricorn Metals, are flagged as potentially trading significantly below their intrinsic value, presenting opportunities for discerning investors.

Feb 2, 2026

Business

Beyond the Scale: How the GLP-1 Boom is Reshaping Diets, Wallets, and Industries

The surge in popularity of weight-loss drugs like Ozempic and Wegovy is sending shockwaves far beyond the pharmacy, fundamentally altering consumer spending, challenging major corporations, and forcing a broad economic recalibration.

Feb 2, 2026

Business

A $21 Million Vote of Confidence: Major Fund Bets on Moelis & Company Amid M&A Lull

Capital Management Corp's significant stake increase in investment bank Moelis & Company is being viewed by market observers as a strategic wager on a potential rebound in mergers and acquisitions activity.

Feb 2, 2026

Business

Studio Upheaval and Mass Layoffs Cast Shadow Over Long-Awaited MMO Ashes of Creation

The future of the Kickstarter-funded MMORPG Ashes of Creation is in jeopardy following the resignation of its founder and a wave of senior departures, triggering significant staff cuts and leaving the community in limbo.

Feb 2, 2026

Business

Beyond the GLP-1 Hype: Is Novo Nordisk's Diversified Pipeline Its Hidden Strength?

While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.

Feb 2, 2026

Business

Robocap Exits Entire NICE Stake Amid AI Pivot and Prolonged Underperformance

London-based investment firm Robocap Asset Management has liquidated its entire $5.1 million position in NICE Ltd., as the cloud software company navigates a challenging strategic shift to AI-centric solutions against a backdrop of significant stock decline.

Feb 2, 2026

Business

Medtronic Stock: Analysts See Upside Despite Market Underperformance

While Medtronic's shares have trailed the S&P 500 over the past year, Wall Street maintains a cautiously optimistic stance, buoyed by strong recent earnings and raised guidance.

Feb 2, 2026

Novo's CagriSema Shows Strong Dual Benefits in Diabetes Trial, But Faces Stiff Competition

Novo Nordisk's experimental combination therapy CagriSema has demonstrated superior blood sugar control and weight loss compared to its own blockbuster Wegovy in a major Phase 3 trial. However, the emerging data suggests it may still trail behind Eli Lilly's rival drug Zepbound in key efficacy measures, setting the stage for a fierce market battle.

Feb 2, 2026